MAPT and dementia: Established core biomarkers (i.e., Aβ1–42, t-tau, and p-tau) have high diagnostic accuracy in discriminating individuals with AD from subjects without cognitive disturbances, but their diagnostic performance in differentiating AD from other dementias is far from optimal [38].